How to Sell Peptides Online and Keep Your Payments Running

Almost every payment problem a peptide business has starts with an unclear model. Underwriters, regulators and card schemes all ask the same question: who is this product for, and what is it for?

• Research supply: peptides sold for laboratory research to institutions and businesses, with no human use.
• Prescription dispensing: peptides dispensed by a licensed pharmacy on a valid prescription, often through a telehealth service.
• Cosmetic peptides: peptides in skincare products, regulated as cosmetics.
• Food and supplements: collagen peptides and similar products sold as food or dietary supplements.

A 'research use only' or 'not for human use' label does not settle how a product is treated. In warning letters dated December 2024, December 2025, March 2026 and August 2026, the FDA treated online peptide and research-chemical products as unapproved new drugs despite such labels, because the websites and social media pointed to human use.

Underwriters apply the same logic. If a research store shows dosing guides, cycle stacks, before-and-after photos or products bundled by body outcome, they read it as a consumer health store, whatever the label says.

• No human-use claims, dosing instructions, cycle guides or injection content anywhere on the site or linked social media.
• No before-and-after content, testimonials about results or products grouped by fitness or body goals.
• Certificates of analysis and purity data for each batch.
• Terms of sale limited to research use, with a process to verify that buyers are institutions or businesses.
• Affiliate and influencer content held to the same rules, because underwriters read it as part of your marketing.

If peptides are dispensed on prescription, expect to show pharmacy licences for every state or country you ship to, how prescriptions are issued and verified, and who the prescribers are. Prescription and pharmacy models are typically coded under MCC 5912 or 5122, which Visa places in Tier 1 of its Integrity Risk Program, and acquirers commonly ask for third-party healthcare merchant certification such as LegitScript.

US compounding rules are moving. On 15 April 2026 the FDA announced the removal of 12 peptides, including BPC-157 and TB-500, from its Category 2 list of bulk substances that raise significant safety concerns, and in July 2026 its advisory committee voted to recommend six of them for the 503A bulks list. Neither step is an approval, and formal rulemaking still has to follow, so check the current status before you rely on it.

Under EU and UK medicines law, a product presented as treating or preventing disease, or used to restore, correct or modify body functions through a pharmacological, immunological or metabolic action, is a medicinal product and needs authorisation. Peptides in skincare are regulated as cosmetics. Acquirers check that your products and claims fit the rules in each market you sell to, so list your markets honestly and block those you do not serve.

• A clear description of your model and the products you sell.
• The live website, including product pages, blog and social media.
• Company documents and the identity of owners and directors.
• Licences and certification where relevant, such as pharmacy licences or LegitScript.
• Certificates of analysis and supplier details.
• The markets you ship to and how you verify customers.
• Processing history, refund and chargeback ratios, and any past account closures.

Peptide accounts are usually closed for one of four reasons: the category is on the processor's prohibited list, the website contradicts how the business was described at signup, the merchant category code does not match the real business, or disputes run above what the processor accepts. A closure can come with funds held and a listing on Mastercard's MATCH list for five years.

The fix is the same in every case. Apply to providers whose policy covers your model, describe the business exactly as it is, and keep the website consistent with that description.

Acquipayer is not a payment provider. You describe your model, products, markets, licences and volumes once, and your profile is matched with a payment provider whose policy accepts peptide businesses like yours. Your account is then prepared with that provider. Final approval and terms are always the provider's decision.

• US Food and Drug Administration, warning letters to online peptide and research-chemical sellers, December 2024 to August 2026.
• US Food and Drug Administration, update on Category 2 bulk drug substances, 15 April 2026, and Pharmacy Compounding Advisory Committee, July 2026.
• Directive 2001/83/EC, definition of a medicinal product.
• Visa Integrity Risk Program, in effect since May 2023.
• LegitScript, healthcare merchant certification.